Cleared Traditional

K900343 - GAP-IGG (FDA 510(k) Clearance)

Class I Microbiology device.

K900343 · Biomerica, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1991
Decision
576d
Days
Class 1
Risk

K900343 is an FDA 510(k) clearance for the GAP-IGG. Classified as Helicobacter Pylori (product code LYR), Class I - General Controls.

Submitted by Biomerica, Inc. (Newport Beach, US). The FDA issued a Cleared decision on August 22, 1991 after a review of 576 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3110 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Biomerica, Inc. devices

Submission Details

510(k) Number K900343 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 23, 1990
Decision Date August 22, 1991
Days to Decision 576 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
474d slower than avg
Panel avg: 102d · This submission: 576d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code LYR Helicobacter Pylori
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3110
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.